Waters Corporation (WAT) SEC Filings & Earnings Calls
EquiReason read 16 Waters Corporation SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement).
Source: SEC EDGAR filings · figures as of 2026-07-04 · read by EquiReason
- Market cap
- 44.6B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
Every filing, read
last 12 months · SECWhat happened, the numbers inside, guidance and risks. The original is one click away.
21 Aug 20268-K · 5.02, 8.01Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Leadership transition in key division may cause short-term disruption.
“Resignation of Senior VP, Analytical Sciences Division effective immediately.”
11 Aug 202610-QWaters reported Q2 2026 results with total revenue up 113% YoY to $1.645B, but operating loss of $86M due to acquisition-related costs.earningsopen
Figures in the filing · each found in the filing text
| Total net revenues · Q2-2026 | $1.65B | +113% y/y |
| Total net revenues · H1-2026 | $2.91B | +103% y/y |
| Net (loss) income · Q2-2026 | $-136M | -193% y/y |
| Net (loss) income · H1-2026 | $-208M | -178% y/y |
| Operating (loss) income · Q2-2026 | $-86M | -146% y/y |
| Operating (loss) income · H1-2026 | $-134M | -139% y/y |
| Net cash provided by operating activities · H1-2026 | $198M | -34% y/y |
| Analytical & Materials Sciences revenue · Analytical & Materials Sciences · Q2-2026 | $756M | +7% y/y |
| Biosciences revenue · Biosciences · Q2-2026 | $368M | |
| Advanced Diagnostics revenue · Advanced Diagnostics · Q2-2026 | $521M | +740% y/y |
Risks flagged
Tariff and trade policy uncertainty
“These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company’s consolidated statement of operations and statement of cash flows.” · word for word
Integration risk from BDS acquisition
“failure to realize the anticipated benefits of the BDS Business Acquisition, including as a result of delay in integrating the businesses of the Company and SpinCo, on the expected timeframe or at all” · word for word
High debt levels
“As of July 4, 2026, the Company had a total of $5.1 billion in outstanding debt” · word for word
4 Aug 20268-K · 2.02Waters Q2 2026: revenue $1.645B beat guidance, organic +9% cc, Adj. EPS $3.05. Raising FY26 guidance: organic cc growth 7-9% (from prior), Adj. EPS $14.45-14.65 (10-12% growth). Q3 guidance also raised. Broad-based end-market recovery.open
Figures in the filing · each found in the filing text
| Total reported revenue · Q2-2026 | $1.65B | |
| Organic revenue · Q2-2026 | $828M | +7% y/y |
| Biosciences and Diagnostic Solutions revenue · Biosciences and Diagnostic Solutions · Q2-2026 | $817M | +4% y/y |
| Adjusted EPS · Q2-2026 | $3.05 | +3% y/y |
| GAAP diluted EPS · Q2-2026 | $-1.39 | -156% y/y |
| ASD revenue · Analytical Sciences Division · Q2-2026 | $669M | +7% y/y |
| Biosciences Division revenue · Biosciences Division · Q2-2026 | $368M | +3% y/y |
| Diagnostic Solutions revenue · Advanced Diagnostics Division · Q2-2026 | $449M | +6% y/y |
| Clinical Business Unit revenue · Advanced Diagnostics Division · Q2-2026 | $72M | +16% y/y |
| Materials Sciences Division revenue · Materials Sciences Division · Q2-2026 | $87M | +6% y/y |
Guidance
FY26 organic constant currency revenue growth raised to 7.0-9.0% from prior; acquired business revenue ~$3.045B; total revenue $6.415-6.476B; Adj. EPS $14.45-14.65 (10-12% growth). Q3: organic cc growth 8-10%, total revenue $1.745-1.762B, Adj. EPS $3.95-4.05 (16-19% growth).
Full-year FY26 guidance raised across all components: organic revenue growth, acquired business revenue, and adjusted EPS. Q3 guidance also raised. Management cites broad-based end-market recovery and momentum.
Risks flagged
GAAP loss per share of $1.39 due to acquisition-related charges, including amortization of intangibles and inventory step-up.
“On a GAAP basis, the Company reported a diluted loss per share of $1.39 for the second quarter of 2026, compared to diluted EPS of $2.47 for the second quarter of 2025, reflecting acquisition-related purchase accounting charges, including amortization of acquired intangibles and inventory step-up.” · word for word
Unfavorable foreign exchange translation impacted results, partially offset by cost actions.
“Adjusted EPS of $3.05 landed at the high end of the guidance range, as early cost actions offset unfavorable foreign exchange translation.” · word for word
12 May 202610-QTotal net revenues $1.27B (+91% y/y); Net (loss) income $-72M (-160% y/y); Operating cash flow $-3M (-101% y/y)open
Figures in the filing · each found in the filing text
| Total net revenues · Q1-2026 | $1.27B | +91% y/y |
| Net (loss) income · Q1-2026 | $-72M | -160% y/y |
| Operating cash flow · Q1-2026 | $-3M | -101% y/y |
| Analytical & Materials Sciences revenue · Analytical & Materials Sciences · Q1-2026 | $686M | +13% y/y |
| Biosciences revenue · Biosciences · Q1-2026 | $232M | |
| Advanced Diagnostics revenue · Advanced Diagnostics · Q1-2026 | $349M | +559% y/y |
| Segment operating income · Total segments · Q1-2026 | $389M | +66% y/y |
Risks flagged
Tariff and trade policy risk
“These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company’s consolidated statement of operations and statement of cash flows.” · word for word
Integration risk from BDS acquisition
“failure to realize the anticipated benefits of the BDS Business Acquisition, including as a result of delay in integrating the businesses of the Company and SpinCo, on the expected timeframe or at all” · word for word
High debt burden
“As of April 4, 2026, the Company had a total of $5.3 billion in outstanding debt” · word for word
China economic and regulatory risk
“economic conditions in China, trade tensions and tariffs between the U.S. and China and their impact on our business, increased competition from local and international competitors in China” · word for word
5 May 20268-K · 2.02Total Reported Revenue $1.27B; Organic Revenue $747M (+13% y/y); Acquired Business Revenue (owned-period) $520M; Guidance: Full-year organic constant currency growth raised to 6.5%-8.0%; adjusted EPS raised to $14.40-$14.60.earningsopen
Figures in the filing · each found in the filing text
| Total Reported Revenue · Q1-2026 | $1.27B | |
| Organic Revenue · Q1-2026 | $747M | +13% y/y |
| Acquired Business Revenue (owned-period) · Biosciences and Diagnostic Solutions · Q1-2026 | $520M | |
| GAAP Diluted EPS · Q1-2026 | $-0.87 | |
| Adjusted EPS · Q1-2026 | $2.70 | +20% y/y |
| Analytical Sciences Division Revenue · Analytical Sciences Division · Q1-2026 | $607M | |
| Biosciences Division Revenue · Biosciences Division · Q1-2026 | $232M | |
| Advanced Diagnostics Division Revenue · Advanced Diagnostics Division · Q1-2026 | $288M | |
| Materials Sciences Division Revenue · Materials Sciences Division · Q1-2026 | $79M | |
| Full-Year 2026 Total Company Reported Revenue Guidance · FY2026 | $6.43B |
Guidance
Full-year organic constant currency growth raised to 6.5%-8.0%; adjusted EPS raised to $14.40-$14.60.
Guidance raised across all metrics; strong demand and margin expansion; acquired businesses outperforming.
Risks flagged
Integration risk from large acquisition of BD Biosciences and Diagnostic Solutions; execution is key to realizing synergies.
“Acquisition closed on February 9, 2026; integration and synergy realization are ongoing.”
GAAP loss per share due to acquisition-related charges; adjusted metrics may mask underlying costs.
“GAAP diluted loss per share of $0.87 due to acquisition-related purchase accounting charges including amortization of acquired intangibles and inventory step-up.”
9 Apr 2026DEF 14AWaters Corporation filed its definitive proxy statement, detailing the completed acquisition of BD's Biosciences & Diagnostic Solutions businesses and providing a comprehensive overview of executive compensation and corporate governance.open
Figures in the filing · each found in the filing text
| Revenue Growth · FY2025 | 7.0% | |
| Recurring Revenue Growth · FY2025 | 8.0% | |
| Adjusted Diluted EPS · FY2025 | $13.13 | +11% y/y |
| Pharmaceutical End Market Sales Growth · Pharmaceutical · FY2025 | 9.0% | |
| GAAP Net Income · FY2025 | $643M | +1% y/y |
| Adjusted Non-GAAP Organic Net Income · FY2025 | $763M | +8% y/y |
Risks flagged
Integration Risk from BD Acquisition
“The Board of Directors rigorously evaluated the transaction and continues to actively oversee integration to ensure we capture the opportunities inherent in this combination.” · word for word
23 Mar 20268-K · 1.01, 2.03, 8.01Waters subsidiary issued $3.5B senior notes across five tranches to refinance existing debt. No guidance or operating metrics.open
Figures in the filing · each found in the filing text
| Senior notes 2027 · Q1-2026 | $650M | |
| Senior notes 2029 · Q1-2026 | $600M | |
| Senior notes 2031 · Q1-2026 | $750M | |
| Senior notes 2033 · Q1-2026 | $750M | |
| Senior notes 2036 · Q1-2026 | $750M |
Risks flagged
Increased leverage from debt issuance
“$3.5 billion in new senior notes; used to repay existing term loan”
23 Feb 202610-KTotal Net Sales $3.17B (+7% y/y); Net Income $643M (+1% y/y); Operating Cash Flow $653M (-14% y/y)open
Figures in the filing · each found in the filing text
| Total Net Sales · FY2025 | $3.17B | +7% y/y |
| Net Income · FY2025 | $643M | +1% y/y |
| Operating Cash Flow · FY2025 | $653M | -14% y/y |
| China Net Sales · Asia · FY2025 | $437M | +10% y/y |
| Pharmaceutical Net Sales · Pharmaceutical · FY2025 | $1.87B | +9% y/y |
| Chemistry Consumables Net Sales · Waters · FY2025 | $631M | +12% y/y |
| Waters Instrument Systems Net Sales · Waters · FY2025 | $1.10B | +7% y/y |
| TA Net Sales · TA · FY2025 | $352M | -1% y/y |
| Operating Income as % of Sales · FY2025 | 25.4% | |
| Capital Expenditures · FY2025 | $113M | -20% y/y |
Risks flagged
Tariff and Trade Policy Uncertainty
“These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company's consolidated statement of operations and statement of cash flows.” · word for word
BDS Acquisition Integration and Debt
“The Company plans to refinance the $3.5 billion tranche in the first quarter of 2026 with long-term bond financing. There can be no assurance that the Company will be able to do so on commercially reasonable terms or at all.” · word for word
ERP Implementation Disruption
“The Company anticipates spending approximately $130 million in connection with the implementation of the new ERP system, of which $52 million has been spent on capitalized software and operating expenses through the end of 2025.” · word for word
9 Feb 20268-K · 1.01, 2.01, 2.03, 5.02, 7.01Waters Corp completed acquisition of BDS Business from BD via a Reverse Morris Trust transaction, issuing ~39.2% of Waters stock to BD shareholders. Also incurred debt financing and appointed a new director.acquisitionopen
Figures in the filing · each found in the filing text
| Acquired Business Revenue Contribution · BDS · FY2026 | $3.00B | |
| Total Company Revenue Guidance · FY2026 | $6.41B |
Risks flagged
Integration risk: Large acquisition requires successful integration of operations, culture, and systems.
“Transformative acquisition of BD Biosciences; significant scale increase and synergy targets.”
Dilution risk: Issuance of 39.2% of Waters' shares to BD shareholders dilutes existing holders.
“Approximately 39.2% of the outstanding shares of Waters Common Stock on a fully diluted basis issued.” · word for word
9 Feb 20268-K · 2.02Sales $932M (+7% y/y); Full-Year Sales $3.17B (+7% y/y); Non-GAAP EPS $4.53 (+10% y/y); Guidance: FY2026 organic growth 5.5-7.0%; total revenue $6.405-6.455B; non-GAAP EPS $14.30-14.50 (+8.9-10.4% YoY)earningsopen
Figures in the filing · each found in the filing text
| Sales · Q4-2025 | $932M | +7% y/y |
| Full-Year Sales · FY2025 | $3.17B | +7% y/y |
| Non-GAAP EPS · Q4-2025 | $4.53 | +10% y/y |
| Full-Year Non-GAAP EPS · FY2025 | $13.13 | +11% y/y |
| GAAP EPS · Q4-2025 | $3.77 | |
| Chemistry Growth · Chemistry · Q4-2025 | 12.0% | |
| Recurring Revenue Growth · FY2025 | 8.0% |
Guidance
FY2026 organic growth 5.5-7.0%; total revenue $6.405-6.455B; non-GAAP EPS $14.30-14.50 (+8.9-10.4% YoY)
Strong guidance with organic growth acceleration and significant contribution from BD acquisition. EPS growth expected to be double-digit.
Risks flagged
Integration risk: BD Biosciences acquisition adds complexity; synergy realization may take time.
“Transformative acquisition of BD Biosciences; cost synergies expected but execution risk.”
Currency risk: constant currency growth higher than reported due to FX headwinds.
“Sales grew 7% as reported and 6% in constant currency in Q4; full-year 7% as reported and 7% in constant currency.”
27 Jan 20268-K · 5.07, 7.01, 8.01Submitted matters to a vote of security holders; issued a Regulation FD disclosure (forward guidance or material update)open
Risks flagged
Integration risk from combining BD's business with Waters
“combination of BD's Biosciences & Diagnostic Solutions business with Waters” · word for word
16 Jan 20268-K · 8.01Disclosed a material event under other events (litigation, recall, contract loss, or major announcement)open
Risks flagged
Litigation risk: two stockholder lawsuits filed alleging inadequate disclosures.
“Two lawsuits filed in New York Supreme Court; demand letters received.”
Execution risk: merger may not close if stockholders vote against or regulatory issues arise.
“Pending stockholder vote and regulatory approvals.”
12 Jan 20268-K · 7.01Issued a Regulation FD disclosure (forward guidance or material update); filed financial statements and exhibits with this reportopen
Risks flagged
Proposed transaction with BD and SpinCo subject to regulatory approvals and other closing conditions; may not be completed.
“statements regarding the proposed transaction among Waters Corporation... Becton, Dickinson and Company and Augusta SpinCo Corporation... one or more closing conditions to the transaction, including certain regulatory approvals, may not be satisfied or waived” · word for word
4 Nov 202510-QSolid revenue growth driven by pharmaceutical demand, but operating margin compressed by merger-related costs and ERP implementation.earningsopen
Figures in the filing · each found in the filing text
| Total net sales · Q3-2025 | $800M | +8% y/y |
| Net income · Q3-2025 | $149M | -8% y/y |
| Operating income as a % of sales · Q3-2025 | 24.0% | |
| Net cash provided by operating activities · 9M-2025 | $488M | -7% y/y |
| Waters instrument systems sales · Waters · Q3-2025 | $282M | +6% y/y |
| Waters chemistry consumables sales · Waters · Q3-2025 | $158M | +14% y/y |
| Waters service sales · Waters · Q3-2025 | $273M | +9% y/y |
| TA net sales · TA · Q3-2025 | $87M | +2% y/y |
| Pharmaceutical sales · Q3-2025 | $480M | +12% y/y |
| China sales · Q3-2025 | $114M | +13% y/y |
Risks flagged
Merger execution risk
“The transaction is expected to close around the end of the first quarter of calendar year 2026, subject to receipt of required regulatory approvals, shareholder approval from the Company's shareholders and satisfaction of other customary closing conditions.” · word for word
Tariff and trade policy risk
“These tariffs, any resulting retaliatory tariffs and any related supply-chain disruptions could have a significant impact on the Company's consolidated statement of operations and statement of cash flows.” · word for word
U.S. government shutdown impact
“the U.S. government shutdown that began in October 2025...may be exacerbated by the U.S. government shutdown that began in October 2025.” · word for word
4 Nov 20258-K · 2.02Sales $800M (+8% y/y); GAAP diluted EPS $2.50 (-8% y/y); Non-GAAP EPS $3.40 (+16% y/y); Guidance: Full-year constant currency sales growth guidance raised to +6.7% to +7.3%; non-GAAP EPS to $13.05-$13.15.earningsopen
Figures in the filing · each found in the filing text
| Sales · Q3-2025 | $800M | +8% y/y |
| GAAP diluted EPS · Q3-2025 | $2.50 | -8% y/y |
| Non-GAAP EPS · Q3-2025 | $3.40 | +16% y/y |
Guidance
Full-year constant currency sales growth guidance raised to +6.7% to +7.3%; non-GAAP EPS to $13.05-$13.15.
Raised full-year guidance driven by strong Q3 results and continued pharma demand.
Risks flagged
Integration risk from BD acquisition; execution on synergies is critical.
“Integration planning is progressing as expected, but significant cost and revenue synergies are yet to be realized.”
Currency translation could impact reported results; guidance includes currency assumptions.
“Net of currency translation, the Company is raising its full-year 2025 reported sales growth to the range of +6.5% to +7.1%.” · word for word
Waters Corporation — questions
- What did Waters Corporation file recently?
- 16 SEC filings in the last 12 months. Latest: 8-K on 2026-08-21 — Reported the departure of a director or principal officer (CEO/CFO change); disclosed a material event under other events (litigation, recall, contract loss, or major announcement)
Every figure on this page comes from Waters Corporation's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.